학술논문
PP72 Demonstration of dose-dependent target inhibition using a quantitative biomarker assay for SB939, a potent, orally active HDAC inhibitor, in a Phase I clinical study in solid tumors
Document Type
Abstract
Author
Source
In EJC Supplements 2009 7(4):26-26
Subject
Language
ISSN
1359-6349